Cystic Fibrosis Phase 2 Trial of Drug Aiming to Stabilize Key CF Gene Underway

http://cysticfibrosisnewstoday.com/2015/12/02/cystic-fibrosis-phase-2-trial-drug-aiming-stabilize-key-cf-gene-underway/

Published originally in Cystic Fibrosis News Today
By Charles Moore

Nivalis Therapeutics, Inc., a Boulder, Colorado-based clinical stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of its lead investigational drug, N91115, a stabilizer Continue reading Cystic Fibrosis Phase 2 Trial of Drug Aiming to Stabilize Key CF Gene Underway

Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 multiple ascending dose clinical trial with CTP-656. CTP-656 (deuterium-modified ivacaftor) is a novel, potentially disease-modifying Continue reading Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Vertex Pharmaceuticals (NASDAQ:VRTX) released outstanding third-quarter earnings on Wednesday with sales of both cystic fibrosis drugs, Orkambi and Kalydeco, selling like hotcakes. Continue reading Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Concert Pharma (CNCE) Announces Results of CTP-656 Phase 1; Demonstrated Superior PK Profile to Kalydeco

Concert Pharma (NASDAQ: CNCE) announced positive data from a Phase 1 single ascending dose clinical trial of CTP-656. CTP-656 is a novel deuterium-modified version of ivacaftor, which is commercially available as a single agent under the name Kalydeco® and as part of a fixed-dose combination therapy called Continue reading Concert Pharma (CNCE) Announces Results of CTP-656 Phase 1; Demonstrated Superior PK Profile to Kalydeco

Two New Potent DF508-CFTR Correctors Offer Potential to Treat Cystic Fibrosis

An international group of researchers led by Aleksander Edelman from Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes) discovered two novel compounds that can target the genetic mutation that leads to a severe form of Cystic Fibrosis. Continue reading Two New Potent DF508-CFTR Correctors Offer Potential to Treat Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis

Concert Pharmaceuticals, Inc. CNCE, +6.72% today announced that is has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis. Ivacaftor is commercially available under the name Kalydeco®. The first Phase 1 Continue reading Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis